These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 26083155)

  • 21. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy.
    Milazzo L; Lai A; Calvi E; Ronzi P; Micheli V; Binda F; Ridolfo AL; Gervasoni C; Galli M; Antinori S; Sollima S
    HIV Med; 2017 Apr; 18(4):284-291. PubMed ID: 27477612
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Treatment of hepatitis C].
    Schneider MD; Kronenberger B; Zeuzem S; Sarrazin C
    Internist (Berl); 2015 Apr; 56(4):391-405. PubMed ID: 25762008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of hepatitis C virus genotype 3-infection.
    Pol S; Vallet-Pichard A; Corouge M
    Liver Int; 2014 Feb; 34 Suppl 1():18-23. PubMed ID: 24373074
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimal therapy in genotype 4 chronic hepatitis C: finally cured?
    Abdel-Razek W; Waked I
    Liver Int; 2015 Jan; 35 Suppl 1():27-34. PubMed ID: 25529085
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Geno2pheno[HCV] - A Web-based Interpretation System to Support Hepatitis C Treatment Decisions in the Era of Direct-Acting Antiviral Agents.
    Kalaghatgi P; Sikorski AM; Knops E; Rupp D; Sierra S; Heger E; Neumann-Fraune M; Beggel B; Walker A; Timm J; Walter H; Obermeier M; Kaiser R; Bartenschlager R; Lengauer T
    PLoS One; 2016; 11(5):e0155869. PubMed ID: 27196673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HCV Genotype 6a Escape From and Resistance to Velpatasvir, Pibrentasvir, and Sofosbuvir in Robust Infectious Cell Culture Models.
    Pham LV; Ramirez S; Gottwein JM; Fahnøe U; Li YP; Pedersen J; Bukh J
    Gastroenterology; 2018 Jun; 154(8):2194-2208.e12. PubMed ID: 29454794
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.
    Lawitz E; Poordad FF; Pang PS; Hyland RH; Ding X; Mo H; Symonds WT; McHutchison JG; Membreno FE
    Lancet; 2014 Feb; 383(9916):515-23. PubMed ID: 24209977
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection.
    Klibanov OM; Gale SE; Santevecchi B
    Ann Pharmacother; 2015 May; 49(5):566-81. PubMed ID: 25680759
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy, Safety, and Predictors of Direct-acting antivirals in Hepatitis C Virus Patients with Heterogeneous Liver Diseases.
    De Pace V; Morelli MC; Ravaioli M; Maggi F; Galli S; Vero V; Re MC; Cescon M; Pistello M
    New Microbiol; 2019 Oct; 42(4):189-196. PubMed ID: 31609453
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens.
    Akuta N; Sezaki H; Suzuki F; Fujiyama S; Kawamura Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2017 Jul; 89(7):1248-1254. PubMed ID: 28079269
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Short article: Retreatment of chronic hepatitis C virus infection after unsuccessful therapy with all-oral direct-acting antiviral regimens: a real-life experience.
    Milazzo L; Magni C; Niero F; Schiavini M; Lai A; Cento V; Binda F; Antinori S; Sollima S
    Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1231-1234. PubMed ID: 28877086
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review.
    Yau AH; Yoshida EM
    Can J Gastroenterol Hepatol; 2014 Sep; 28(8):445-51. PubMed ID: 25229466
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current race in the development of DAAs (direct-acting antivirals) against HCV.
    De Clercq E
    Biochem Pharmacol; 2014 Jun; 89(4):441-52. PubMed ID: 24735613
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The value of cure associated with treating treatment-naïve chronic hepatitis C genotype 1: Are the new all-oral regimens good value to society?
    Younossi ZM; Park H; Dieterich D; Saab S; Ahmed A; Gordon SC
    Liver Int; 2017 May; 37(5):662-668. PubMed ID: 27804195
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvant ribavirin and longer direct-acting antiviral treatment duration improve sustained virological response among hepatitis C patients at risk of treatment failure.
    Lu M; Wu KH; Li J; Moorman AC; Spradling PR; Teshale EH; Boscarino JA; Daida YG; Schmidt MA; Rupp LB; Zhang T; Trudeau S; Gordon SC
    J Viral Hepat; 2019 Oct; 26(10):1210-1217. PubMed ID: 31197910
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interferon-free therapy for hepatitis C: The hurdles amid a golden era.
    Colombo M
    Dig Liver Dis; 2015 Sep; 47(9):727-33. PubMed ID: 25937625
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ombitasvir/paritaprevir/ritonavir and dasabuvir with or without sofosbuvir for patients with hepatitis C virus genotype 1 infection who failed a prior course of direct-acting antiviral therapy.
    Poordad F; Bennett M; Sepe TE; Cohen E; Reindollar RW; Everson G; Phillips RW; Siddique A; Sullivan JG; Pilot-Matias T; Abunimeh M; Cohen DE; Younes Z
    J Med Virol; 2019 Jul; 91(7):1307-1312. PubMed ID: 30840774
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatitis C therapy: highlights from the 2012 annual meeting of the European Association for the Study of the Liver.
    Barreiro P; Vispo E; Poveda E; Fernández-Montero JV; Soriano V
    Clin Infect Dis; 2013 Feb; 56(4):560-6. PubMed ID: 23090932
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nonstructural protein 5A resistance profile in patients with chronic hepatitis C treated with ledipasvir-containing regimens without sofosbuvir.
    Kitrinos KM; Corsa AC; Worth A; Hedskog C; Brainard DM; Miller MD; Mo H
    J Viral Hepat; 2018 Feb; 25(2):126-133. PubMed ID: 28833932
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge.
    De Monte A; Courjon J; Anty R; Cua E; Naqvi A; Mondain V; Cottalorda J; Ollier L; Giordanengo V
    J Clin Virol; 2016 May; 78():27-30. PubMed ID: 26967675
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.